Herein, bioinformatics methods were used for constructing an innovative HDACs-related prognostic signature, which consists of five genes (BRD2, PBRM1, HDAC3, TAF1, and BRD3) was used to divide COAD patients with different outcomes. This evidence concerns the gene BRD2 and colon adenocarcinoma.